11/30/2009

Theravance failed to gain FDA approval to market telavancin, an injectable antibiotic, as a treatment for nosocomial pneumonia. The drug developer said it has the information and analyses needed to address the agency's complete-response letter.

Full Story:
Reuters

Related Summaries